- Home
- COEP vs PYPD Comparison
COEP vs PYPD Comparison
Compare COEP & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- PYPD
- Stock Information
- Founded
- COEP 2017
- PYPD 2008
- Country
- COEP United States
- PYPD Israel
- Employees
- COEP N/A
- PYPD N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- PYPD Medical/Dental Instruments
- Sector
- COEP Health Care
- PYPD Health Care
- Exchange
- COEP Nasdaq
- PYPD Nasdaq
- Market Cap
- COEP 32.0M
- PYPD 35.3M
- IPO Year
- COEP N/A
- PYPD 2020
- Fundamental
- Price
- COEP $7.48
- PYPD $3.49
- Analyst Decision
- COEP
- PYPD Strong Buy
- Analyst Count
- COEP 0
- PYPD 5
- Target Price
- COEP N/A
- PYPD $11.40
- AVG Volume (30 Days)
- COEP 31.9K
- PYPD 1.4M
- Earning Date
- COEP 08-15-2025
- PYPD 08-13-2025
- Dividend Yield
- COEP N/A
- PYPD N/A
- EPS Growth
- COEP N/A
- PYPD N/A
- EPS
- COEP N/A
- PYPD N/A
- Revenue
- COEP $62,874.00
- PYPD N/A
- Revenue This Year
- COEP N/A
- PYPD N/A
- Revenue Next Year
- COEP N/A
- PYPD N/A
- P/E Ratio
- COEP N/A
- PYPD N/A
- Revenue Growth
- COEP N/A
- PYPD N/A
- 52 Week Low
- COEP $2.31
- PYPD $2.30
- 52 Week High
- COEP $13.70
- PYPD $4.42
- Technical
- Relative Strength Index (RSI)
- COEP 39.31
- PYPD 55.68
- Support Level
- COEP $7.21
- PYPD $3.42
- Resistance Level
- COEP $8.86
- PYPD $3.62
- Average True Range (ATR)
- COEP 0.59
- PYPD 0.19
- MACD
- COEP -0.03
- PYPD -0.02
- Stochastic Oscillator
- COEP 32.98
- PYPD 58.92
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.